|
Idera Pharmaceuticals, Inc. - Company Profile Snapshot
| Company Profile: |
Idera Pharmaceuticals, Inc. |
| Ticker: |
IDRA |
| Exchanges: |
NAS |
| 2008 Sales: |
26,376,000 |
| Major Industry: |
Miscellaneous |
| Sub Industry: |
Medical Services |
| Country: |
UNITED STATES |
| Employees: |
37 |
Business Description
Idera Pharmaceuticals, Inc.. The Company's principal activity is discovering and developing novel therapeutics that modulate immune responses through Toll-like Receptors (TLR). TLRs are specific receptors present in immune system cells that direct the immune system to respond to potential disease threats. The Company discovers and develops synthetic DNA- and RNA-based compounds for the treatment of cancer, infectious diseases, autoimmune diseases, and asthma/allergies and for use as vaccine adjuvants. It has three internal programs, in oncology, infectious diseases, and autoimmune diseases and two collaborative alliances relating to the development of treatments for asthma and allergies and the development of adjuvants for vaccines. The Company is currently conducting a Phase 2 trial of IMO-2055 in oncology and a Phase 1/2 trial of IMO-2055 in combination with chemotherapy in oncology. Its trademarks are IMOtm, Idera(R), IMOxine(R) and GEM(R). The Company operates in the United States.
|
Not the Report you are looking for?
Click here for more browsing options.
|
The following information is available to subscribers or can be accessed by purchasing the Company Profile Report:
|
- Address (mailing), Phone Number, Web Address
- Earnings/Dividends
- Employees
- Exchanges Listed
- Financial Ratio Analysis |
- Recent Stock Performance
- Sales (recent year)
- Senior Officers
- Shareholder Information
- Stock Analysis Summary |
Layout and Content of a Typical Report
|
|
|
|
|
